Chiesi Farmaceutici S.p.a.

Alessandro Accetta

Fabio Rancati

Christine Edwards

Anna Maria Capelli

Patrizia Tisselli

Gurdip Bhalay

Matteo Biagetti

David Edward Clark

Arnaud Jean Francois Auguste Cheguillaume

Laura Carzaniga

Matilde Guala

Michele Retini

Daniele Pala

Andrea Nuzzi

Elizabeth Anne Skidmore

Adele Elisa Pasqua

Roberta Mazzucato

Prashant Bhimrao Kapadnis

Arnaud Jean Fran Ois Auguste Cheguillaume

Arnaud Jean François Auguste Cheguillaume

The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Meta tyrosine derivatives as rho-kinase inhibitors

The invention relates to compounds of formula (I) inhibiting Rho Kinase that are oxidazole derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). 

Oxadiazole derivatives as Rho-Kinase Inhibitors

The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Azaindole derivatives as Rho-kinase inhibitors

The invention relates to compounds of formula (I) inhibiting Rho Kinase that are tyrosine analogues derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). 

Tyrosine analogues derivatives as Rho-kinase inhibitors

Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Tyrosine amide derivatives as Rho-Kinase inhibitors

Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).

Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors

Tyrosine amide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Tyrosine amide derivatives as Rho-kinase inhibitors

Chromene compounds of formula (I), defined herein, inhibit phosphoinositide 3-kinases (PI3K) and are useful for the treatment of disorders associated with a PI3K enzyme mechanism, such as asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis.

Chromene derivatives as phoshoinositide 3-kinases inhibitors

Compounds of formula (I), defined herein, inhibit phosphoinositide 3-kinases (PI3K) and are useful for the treatment of disorders associated with PI3K enzymes.

Indolizine derivatives as phoshoinositide 3-kinases inhibitors

Compounds of formula (I) described herein are useful for inhibiting phosphoinositide 3-kinases (PI3K) and the treatment of disorders associated with PI3K enzymes.

Growing community of inventors

Parma, Italy

Alessandro Accetta